GSK offers the Together with GSK Oncology program for patients who are prescribed a GSK oncology drug (Table).
Together with GSK Oncology
GSK Co-pay Assistance Program
Eligible patients with commercial insurance may receive assistance with their out-of-pocket expenses for Zejula, Ojjaara, or Jemperli
Patient Assistance Program
Uninsured patients who meet eligibility requirements may access medication free of charge through GSK’s Patient Assistance Program.
Zejula Quick Start and Bridge Programs
For patients experiencing delay in coverage at first dispense of Zejula (Quick Start) or coverage interruptions while already on treatment (Bridge), download and fill out the enrollment form, then fax to Together with GSK Oncology at 800-645-9043 to check for eligibility. For access to the form, visit Zejula Enrollment.
In combination with carboplatin and paclitaxel followed by dostarlimab as a single agent for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR), as determined by an FDA-approved test, or microsatellite instability-high; as a single agent for the treatment of adult patients with dMMR recurrent or advanced endometrial cancer, as determined by an FDA-approved test, who have progressed on or following prior treatment with a platinum-containing regimen in any setting and are not candidates for curative surgery or radiation; as a single agent for the treatment of adult patients with dMMR recurrent or advanced solid tumors, as determined by an FDA-approved test, who have progressed on or following prior treatment and who have no satisfactory alternative treatment options
Maintenance treatment of adults with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to first-line platinum-based chemotherapy; maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy, based on an FDA-approved companion diagnostic for niraparib